Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMIS-I: Inhaled CMS in NCFB with P. aeruginosa
NCT03093974Phase 3Completed
- Sponsor
- Zambon
- Start
- Jun 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Non-cystic fibrosis bronchiectasis (NCFB) comparing CMS with Placebo (2 arms). Primary endpoint: Mean Annual Non-cystic Fibrosis Bronchiectasis (NCFB) Pulmonary Exacerbation Rate at 12 months. Started Jun 2017; status: completed.
02
Drugs
colistimethate sodium
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT03093974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093974.